Net income of ~$12-14 mln, which includes the impact of the ~$4 mln success-based regulatory milestone expense in the first quarter of 2012 related to UCERIS and a $10 mln expense for the success-based clinical milestone for RUCONEST in the fourth quarter.
Adjusted EBITDA of ~$29-32 mln.
Co is introducing its financial outlook for full year 2013 as follows:
Net income of approximately $50-54 mln.
Adjusted EBITDA of ~$73-79 mln.
*Co also announced it received FDA approval of UCERIS for the induction of remission in patients with active, mild to moderate ulcerative colitis.
1:30AM Santarus receives FDA approval of UCERIS for the induction of remission in patients with active, mild to moderate ulcerative colitis (SNTS) 11.28 : Co announces the FDA has approved UCERIS extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. The co expects to commence the commercial launch of UCERIS in March 2013.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM